Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sonexa Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Diagnostic evidence of mild to moderate Alzheimer's disease.

• CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.

• A reliable and capable caregiver.

Exclusion Criteria:

• Subjects who reside in a skilled nursing facility.

• Subjects with B12 or folate deficiency.

• Subjects with chronic hepatic disease.

• Subjects with a recent history of hematologic/oncologic disorders.

• Subjects who have experienced a myocardial infarction with the past year.

• Dementia caused or complicated by other organic disease